{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.2","value":"79.9"},{"groupId":"OG001","spread":"101","value":"144"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 1 Day 15/Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"116","value":"167"},{"groupId":"OG001","spread":"145","value":"216"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"Cycle 1 Day 15/3-6 Hr Postdose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"97.5","value":"108"},{"groupId":"OG001","spread":"79.5","value":"92.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"Cycle 4 Day 15/Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"126","value":"167"},{"groupId":"OG001","spread":"140","value":"171"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"title":"Cycle 4 Day 15/3-6 Hr Postdose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets), PO, BID along with cobimetinib, 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 960 mg (four, 240 mg tablets), PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab matching placebo as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21 and vemurafenib 960 mg (four, 240 mg tablets) PO, BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG000","title":"Arm A: Pbo + Cobi + Vem"},{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets) PO, BID along with cobimetinib 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 720 mg (three, 240 mg tablets) PO, BID and vemurafenib matching placebo, PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab 840 mg as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG001","title":"Arm B: Atezo + Cobi + Vem"}],"paramType":"MEAN","populationDescription":"The Cobi PK-evaluable population included all participants who received any dose of cobimetinib 20/40 mg and for whom at least one evaluable PK sample was collected. Number analyzed is the number of participants with data available for analysis at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hour) and 3 to 6 hours post dose on Day 15 of Cycles 1 and 4 (1 Cycle = 28 days)","title":"Plasma Concentration of Cobimetinib Dose: 20/40 mg","type":"SECONDARY","unitOfMeasure":"mg"}